Stocktoria

Lyell Immunopharma, Inc. LYEL

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-06-17

Lyell Immunopharma, Inc. statistics & valuation

Market cap$270.9M
P / B1.1×
Net margin-762355.6%
Return on equity-110.6%
FCF margin-418900.0%
Return on capital-92.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-2636.30% -2349.50% -216.20% -180486.20% -562285.20% -762355.60% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-2732.60% -2016.70% -220.90% -190006.20% -588123.00% -748344.40% 202020212022202320242025
Return on equity (%)
-26.90% -22.00% -35.80% -89.60% -110.60% 202020212022202320242025
Shares outstanding
15.6M 242.7M 249.6M 254.0M 14.7M 21.3M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-22.50% -22.20% -19.50% -31.30% -69.90% -80.70% 202020212022202320242025
Free cash flow margin (%)
-2737.90% -1800.50% -228.90% -127984.60% -266980.30% -418900.00% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$15.69 -$1.84 -$0.74 -$18.70 -$26.23 -$16.06 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-748344.4%-588123.0%-190006.2%-220.9%-2016.7%-2732.6%
Net margin-762355.6%-562285.2%-180486.2%-216.2%-2349.5%-2636.3%
FCF margin-418900.0%-266980.3%-127984.6%-228.9%-1800.5%-2737.9%
Return on assets-80.7%-69.9%-31.3%-19.5%-22.2%-22.5%
Return on equity-110.6%-89.6%-35.8%-22.0%-26.9%69.9%
Current ratio5.287.0616.0717.5913.4012.53

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.